CN Patent

CN104650003A — 一种沃替西汀化合物

Assigned to Tianjin Hankang Pharmaceutical Biotechnology Co Ltd · Expires 2015-05-27 · 11y expired

What this patent protects

本发明属于医药技术领域，具体涉及一种沃替西汀水合物及其制备方法，本发明得到的沃替西汀晶体，含有一个半结晶水，具有的优点：纯度高，稳定性好。本发明还涉及使用这种沃替西汀水合物制造治疗重度抑郁的药物中的应用。

USPTO Abstract

本发明属于医药技术领域，具体涉及一种沃替西汀水合物及其制备方法，本发明得到的沃替西汀晶体，含有一个半结晶水，具有的优点：纯度高，稳定性好。本发明还涉及使用这种沃替西汀水合物制造治疗重度抑郁的药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN104650003A
Jurisdiction
CN
Classification
—
Expires
2015-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Hankang Pharmaceutical Biotechnology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.